Recombinant cytochrome P450 (P450) phenotyping, different approaches for estimating fraction metabolized (f m ), and multiple measures of in vivo inhibitor exposure were tested for their ability to predict drug interaction magnitude in dogs. In previous reports, midazolam-ketoconazole interaction studies in dogs have been attributed to inhibition of CYP3A pathways. However, in vitro phenotyping studies demonstrated higher apparent intrinsic clearances (CL int,app ) of midazolam with canine CYP2B11 and CYP2C21. Application of activity correction factors and isoform hepatic abundance to liver microsome CL int,app values further implicated CYP2B11 (f m > 0.89) as the dog enzyme responsible for midazolam-and temazepam-ketoconazole interactions in vivo. Mean area under the curve (AUC) in the presence of the inhibitor/AUC ratios from intravenous and oral midazolam interaction studies were predicted well with unbound K i and estimates of unbound hepatic inlet inhibitor concentrations and intestinal metabolism using the AUC-competitive inhibitor relationship. No interactions were observed in vivo with bufuralol, although significant interactions with bufuralol were predicted with fluoxetine via CYP2D and CYP2C pathways (>2.45-fold) but not with clomipramine (<2-fold). The minor caffeine-fluvoxamine interaction (1.78-fold) was slightly higher than predicted values based on determination of a moderate f m value for CYP1A1, although CYP1A2 may also be involved in caffeine metabolism. The findings suggest promise for in vitro approaches to drug interaction assessment in dogs, but they also highlight the need to identify improved substrate and inhibitor probes for canine P450s.
Metabolism-mediated drug interactions are an important consideration during preclinical drug lead optimization. Inhibitors of drugmetabolizing enzymes such as cytochromes P450 (P450) may be capable of decreasing the clearance of coadministered drugs when their clearance is metabolic. Therefore, it is important to evaluate new chemical entities as substrates and inhibitors of P450. To speed up this evaluation process, in vitro-in vivo extrapolation methods aimed at predicting metabolic drug interactions have continued to evolve. For instance, the choice of inhibition values (e.g., K i versus unbound K i ) (Brown et al., 2006) , inhibitor absorption rates (Kanamitsu et al., 2000; Brown et al., 2005) , P450 induction , and the choice of in vivo concentrations of P450 inhibitors (Brown et al., 2005; Obach et al., 2005) have all been studied with respect to in vitro-based drug-drug interaction (DDI) predictions. Irreversible enzyme inhibition mechanisms, although recognized for some time, have increasingly been added to in vitro-based drug interaction extrapolation methods with assumptions about the turnover rates of P450 isoforms (Mayhew et al., 2000; Venkatakrishnan and Obach, 2007) . Several of these in vitro findings or approaches have even been integrated into several commercial software packages as biology continues to advance toward more physiological-based modeling.
Other critical factors needed to predict drug interaction magnitude (e.g., AUC i /AUC ratio) are the relative contribution and inhibition levels of each metabolic pathway involved in clearance of a victim drug (Brown et al., 2005; Ito et al., 2005) . Determining the relative fraction metabolized (f m,P450 ) and the inhibition constant K i has traditionally required inhibitors and substrates with high specificity for use in liver microsome incubations. Alternatively, recent studies have suggested that the in vitro fraction metabolized value for human CYP3A4 and CYP2D6 determined with recombinant enzymes was similar to chemical inhibitors used with liver microsomes or hepatocytes at predicting the AUC i /AUC ratio (McGinnity et al., 2008; Youdim et al., 2008) .
Despite the advances in DDI prediction, the lack of probe substrates and probe inhibitors has limited the ability to associate DDIs in nonhuman species with specific P450 enzymes. In veterinary medicine where daily administered pharmaceutical agents are increasingly being pursued for dogs, various drug-metabolizing enzymes have not been extensively studied. Furthermore, several drugs used as P450 probes for human enzymes appear to lack the same degree of specificity and affinity with the dog P450s. For example, quinidine was shown to be a weaker inhibitor of canine CYP2D15 than of human CYP2D6 (Roussel et al., 1998) , canine liver microsomes demonstrate lower activity toward the human CYP2C9 substrate tolbutamide and less inhibition of CYP1A activity by furafylline (Chauret et al., 1997) , and canine CYP2C isoforms demonstrate higher K m values for diclofenac and lower velocities for (S)-mephenytoin than the human CYP2C enzymes (Shou et al., 2003) . These species differences do not preclude the use of liver microsomes for inhibition analysis in nonhuman species, but until specific P450 clearance pathways for drugs are identified, their use may be somewhat limited in discovery screening. With microsomes, all possible drugs that might be coadministered with new chemical entities would need to be evaluated as inhibitors and new chemical entities would need to be evaluated as inhibitors of coadministered drugs. On the other hand, recombinant drug-metabolizing enzymes allow one to catalogue drugs as substrates and/or inhibitors of specific P450s and to perform more targeted screening and DDI assessment. Now that several of the dog hepatic P450s have been cloned and expressed, several new opportunities exist to screen compounds in early drug discovery efforts to characterize their P450 clearance and inhibition profiles. To date, seven P450 cDNA sequences cloned from canine liver have been expressed for study (Shou et al., 2003) , but rP450s have not yet been evaluated for their ability to predict metabolic DDIs. Taking advantage of the Escherichia coli-expressed canine P450s reported recently ), this report describes the use of current in vitro methods to predict in vivo drug interaction magnitude in dogs.
Materials and Methods
Chemicals and Reagents. Substrates, inhibitors, and other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. Phosphate-buffered saline was purchased from Invitrogen (Carlsbad, CA). Metabolite standards for diclofenac, bufuralol, and midazolam were obtained from BD Gentest (Franklin Lakes, NJ). All solvents were acquired from Honeywell Burdick & Jackson (Morristown, NJ). Midazolam solution (5 mg/ml; Abraxis Pharmaceutical, Schaumburg, IL), ketoconazole tablets (200 mg; Teva Pharmaceutical Industries, Ltd., North Wales, PA), temazepam capsules (15 mg; Actavis Elizabeth, Elizabeth, NJ), and fluvoxamine maleate tablets (50 mg; Barr Laboratories, Montvale, NJ) were obtained by Pfizer veterinary staff. Clomipramine HCl was purchased from SigmaAldrich. Racemic bufuralol-HCl and fluoxetine-HCl used for in vivo studies were synthesized within Pfizer. Bufuralol, clomipramine, fluoxetine, and caffeine were added to size number 4 gelatin capsules for dosing. Pooled dog liver microsomes were obtained from XenoTech, LLC (Lenexa, KS), and beagle recombinant cytochrome P450 (rP450) Bactosomes containing beagle P450 reductase were prepared as described previously . Control E. coli Bactosomes were obtained from Cypex Ltd. (Dundee, UK). Beagle plasma was obtained from potassium EDTAtreated blood (Bioreclamation, Inc., Westbury, NY).
Enzyme Kinetics, Intersystem Extrapolation Factor, and f m,P450 Values. Substrate depletion kinetics were carried out with rP450 (50 -150 pmol/ml) or beagle liver microsomes (0.5 mg/ml) as described, using six time points over a 1-h incubation (Baratta et al., 2009) . Caffeine metabolism studies were conducted with higher enzyme concentrations (500 pmol/ml rP450) due to its lower turnover. Low caffeine activity prevented full kinetic profiling, but the relative rates of paraxanthine formation could be characterized with CYP1A1, CYP2B11, and CYP2C21 at 50 M caffeine. Caffeine samples were preincubated at 37°C for 3 min with enzyme, and all reactions were initiated with the addition of substrate to the reaction mixture. The reaction was terminated by the addition of 400 l of cold acetonitrile containing an internal standard and centrifuged at 20,000g for 5 min. A 10-l aliquot of the supernatant was used for analysis.
Substrate titration kinetics for temazepam, diclofenac, bufuralol, and midazolam were determined previously with recombinant CYP2B11, CYP2C21, CYP2D15, and CYP3A12, respectively , and liver microsomes (Aidasani et al., 2008) , which were converted to units of nmol/ min/mg using the microsome lot P450 concentration of 0.462 nmol/mg. 
. V/K and V intersystem extrapolation factor (ISEF) values were determined from rP450 and microsome kinetics as described previously (Proctor et al., 2004; Youdim et al., 2008) using the hepatic expression estimates of 17, 48, 160, 160, and 69 pmol/mg for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A (Sakamoto et al., 1995; Eguchi et al., 1996) . ISEF-corrected activities or relative abundancecorrected activities were then used to calculate f m,P450 values. The relative abundance values used for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A were 0.035, 0.099, 0.331, 0.200, and 0.143 with CYP2D being lower than in pmol/mg units because the values were obtained from separate studies. Ascribing these values to P450 subfamilies should reinforce the fact that they may not differentiate between specific isoforms.
IC 50 and K i Determination. IC 50 values were determined as described from duplicate determinations, except that rP450s were used in place of liver microsomes (25 pmol P450/ml) (Aidasani et al., 2008) . In general, K i was only determined for P450 isoforms exhibiting the lowest IC 50 s for a given victiminhibitor combination. Experiments were performed in triplicate. K i was estimated from IC 50 , and then four inhibitor concentrations were selected for each substrate-enzyme pair (0, 0.5, 4, and 8 times the estimated value). Eight substrate concentrations were then chosen that spanned a range at least 10-fold above and 5-fold below K m . Any cosolvents used in preparation of substrate and inhibitor solutions were normalized across all incubations. Incubations (0.1 ml) contained 25 pmol P450/ml, and they were initiated with a final concentration of 1.0 mM NADPH and quenched after 5 min with acetonitrile containing an internal standard. Nonlinear, global regression fitting to the steady-state competitive inhibition model was then used to determine K i from plots of metabolite formation rate versus substrate concentration (
). Reciprocal replot patterns suggested that all inhibition mechanisms were competitive, although it is recognized that there are reports of noncompetitive inhibition with human recombinant CYP3A4 and ketoconazole.
Protein Binding. Plasma protein binding and Bactosome protein binding of inhibitors were conducted with test compounds at 2 M, near the average plasma levels observed in pharmacokinetic studies. Bactosome protein binding was conducted with control Bactosomes at the same protein levels used in K i experiments (0.1 mg/ml). The Rapid Equilibrium Dialysis apparatus was used for binding studies according to the manufacturer's instructions (Pierce Biosciences, Rockford, IL) and using phosphate-buffered saline in the buffer chambers. Experiments were conducted in quadruplicate and were automated on a Microlab STAR (Hamilton Co., Reno, NV). Plates were incubated on an orbital shaker (90 rpm) uncovered in a CO 2 incubator (5%) at 37°C and 90% humidity for 4 h. Buffer and protein chamber matrices were then matched before precipitating samples with acetonitrile containing an internal standard.
Drug and Dose Selection. All substrates were chosen based on a combination of metabolite selectivity by a particular P450 in vitro and high metabolic clearance in vivo in humans. Inhibitors were chosen primarily based on evidence from liver microsomes that they had high affinity for particular P450s, at least within an order of magnitude of human P450 IC 50 s. Previous evidence for the ability of dogs to tolerate substrates and inhibitors was carefully considered. Some substrates were not thought to be promising probes. For instance, a possible CYP2C substrate such as an arylacetic acid profen was not evaluated due to toleration issues and non-P450 clearance routes, and because dog CYP2C enzymes have lower affinity and/or activity for other CYP2C probe substrates (Chauret et al., 1997; Shou et al., 2003 humans) were chosen for safety reasons in the event of a large interaction, to limit pharmacological effects, and to limit metabolic clearance to the pathways with the highest efficiency. Although dose proportionality was not established for substrates, the doses are in or near the linear pharmacokinetic range for humans. Supratherapeutic doses of the selective serotonin reuptake inhibitors and clomipramine were chosen to maximize the chance of drug interaction with CYP2D15, whereas the ketoconazole dose is within the therapeutic range for dogs. A Ͼ20% increase in the victim drug AUC was targeted. Doses were then calculated based on pharmacokinetics, and IC 50 s determined with liver microsomes and the assumption that f m,in vivo ϭ 1 (eq. 1). No correction for nonspecific protein binding was made at this time because the free drug fraction in plasma and calculation of unbound IC 50 probably would offset each other to some degree. Pharmacokinetic Studies. All pharmacokinetic studies were carried out in compliance with national legislation and subject to local ethical review by an institutional animal care and use committee consisting of internal and external members. Groups of four female research beagles (7-13 kg) were selected to investigate the effects of multiple dosing of putative inhibitors on the pharmacokinetics of victim drugs. Adult dogs (Ͼ2 years) were used because young dogs have underdeveloped xenobiotic metabolism capacity (Aldridge and Neims, 1980; Tanaka et al., 1998) . Dogs were fed their daily allotment of dry food exactly 1 h before dosing. In Phase I, each dog was orally or intravenously administered the victim drugs at the beginning of each study (day 1), and serial blood samples were collected over 24 h for determination of the pharmacokinetics. Capsules and tablets were administered near the back of the mouth. This dose was followed by 2 ml of water delivered to the mouth by syringe to aid in swallowing. Intravenous midazolam was dosed via the cephalic vein. In Phase II, beginning 1 day later, the inhibitor was orally administered once daily for 3 days. On the 3rd day, 1 h after the last dose of inhibitor, the victim was again administered and serial blood samples were collected. Typical collection times were predose, 2 min (for intravenous dosing), 1.0, 1.5, 2.0, 3.0, 5.0, 8.0, and 24 h. Both victim and inhibitor concentrations were measured in plasma. Pharmacokinetic analysis was performed using the noncompartmental approach (linear trapezoidal rule for AUC calculation) over the dosing interval (0 -24 h) with Watson (version 7.2; Thermo Fisher Scientific, Waltham, MA).
Liquid Chromatography/Tandem Mass Spectrometry. Enzyme kinetic, protein binding, and plasma pharmacokinetic study samples were all analyzed using standard sample solvent precipitation, gradient reverse-phase ultraperformance liquid chromatography (UPLC), and positive mode tandem mass spectrometry methods similar to those described previously . The analytical system consisted of a Waters Acquity UPLC system (Waters, Milford, MA) coupled to an API4000 mass spectrometer (Applied Biosystems, Foster City, CA). Caffeine metabolism experiments required careful separation due to some desmethyl metabolites having the same masses and transitions. In this case, separation was accomplished isocratically using an Acquity UPLC BEH HILIC column (2.1 ϫ 50 mm, 1.7 m; Waters) and a mobile phase consisting of 85% water containing 0.1% formic acid and 15% acetonitrile. After caffeine eluted at 1.07 min, the acetonitrile was increased to 70% to wash the column. The flow rate was 0.8 ml/min. Mass spectrophotometric analysis was performed in the positive ion mode using multiple reaction monitoring of the transitions 181 3 124 m/z for paraxanthine (0.56 min) and theophylline (0.62 min), 181 3 138 m/z for theobromine (0.42 min), and 211 3 196 m/z for trimethyluric acid (0.70 min).
Drug Interaction Magnitude Prediction. A common measure of DDI magnitude, the ratio of AUC in the presence of inhibitor to AUC in the absence of inhibitor (AUC i /AUC), was predicted using the competitive inhibitor relationship (Rowland and Matin, 1973) . Inhibition of multiple P450 clearance pathways for a single substrate by a single inhibitor was considered with the use of f m and K i values for each P450 as demonstrated in eq. 1
where x refers to a specific P450 clearance pathway. This approach has been well documented and continues to be evaluated in the drug discovery process (Brown et al., 2005; Obach et al., 2005 Obach et al., , 2006 . Nevertheless, it is still important to recall some important assumptions, such as a well stirred model with rapid inhibitor distribution through the liver, a constant inhibitor concentration in the liver during each pass, passive diffusion of inhibitor into the liver, the victim drug is orally administered and its concentrations ϽK m for each P450 metabolism pathway, and a competitive or noncompetitive P450 inhibition mechanism. Additional terms are needed for intestinal inhibition, and assessment for intravenous administration assumes victims are low extraction drugs with unbound intrinsic clearances that are much lower than hepatic blood flow. Input parameters were selected based on the following logic. K i values used in predictions were determined as described above except that the values were converted to unbound K i (K i,u ) according to the free fraction of inhibitor present in rP450 incubations. Four estimated values of [I] in vivo were tested from the last study day in which victim and perpetrator drugs were coadministered because of the difficulty in characterizing this parameter: 1) free hepatic inlet concentration estimated using the average systemic free plasma concentration, C avg,u (0 -24 h); 2) free hepatic inlet concentration estimated using the maximum systemic free plasma concentration, C max,u ; 3) systemic C avg,u (0 -24 h); and 4) systemic C max,u . The method of Kanamitsu et al. (2000) was used for calculating hepatic inlet inhibitor concentrations (eq. 2):
where C p is either C avg,u or C max,u (corrected for blood partitioning where possible), D is dose, k a is the absorption rate constant (0.03 min Ϫ1 used as the default value), F a is the fraction absorbed, Q h is hepatic blood flow, and f u,b is the free blood fraction. Free inhibitor concentrations were corrected for blood partitioning using the human values for ketoconazole (B:P ϭ 0.69) (Shibata et al., 2008) , fluoxetine (B:P ϭ 0.55), and fluvoxamine (B:P ϭ 0.55) (McGinnity et al., 2008) . A value of B:P was not found for clomipramine therefore a value of 1 was used because the analogs amitriptyline and imipramine have ratios less than 1, but their inhibitory desalkyl metabolites have compensating ratios greater than 1 (Amitai et al., 1993 ). An intermediate value of 35 ml/min/kg for dog liver blood flow was used. The value is similar to that suggested by Davies and Morris (1993) after their review of several published values (30.9 ml/ min/kg).
The f m value used in eq. 1 for each P450-victim pair was derived using estimates of f m,in vivo , and the relative f m,P450 values were determined using either rP450 ISEF or hepatic abundance-corrected CL int,app values as described above. A comprehensive listing of all the calculated f m values evaluated in eq. 1 is provided in supplemental data. Because both f m values are fractions, the f m,in vivo value used in DDI extrapolation, which should reflect turnover to all metabolites by P450, is calculated by multiplication (f m,in vivo ϫ f m,P450 ).
Two estimates of f m,in vivo were evaluated. f m,in vivo ϭ 1 was used as a conservative estimate and then compared with additional f m,in vivo values for oxidative metabolism that were acquired from published excretion studies. High midazolam f m,in vivo values have been observed in excretion studies (0.99) (Smith et al., 1981) , and values Ͼ0.90 have typically been used for human DDI extrapolations. In dogs, no unchanged drug was observed in urine (Vree et al., 1981) , and no reports of fecal excretion could be found. As a result, only f m,in vivo ϭ 1 was evaluated for midazolam. A study using a high dose of temazepam in dogs found high levels of oxazepam, oxazepam glucuronide, and temazepam glucuronide (Schwarz, 1979) . Less than half of the dose was recovered in urine, but approximately 50% of the dose and 50% of total urinary constituents were recovered as oxazepam and oxazepam glucuronide, therefore an f m,in vivo ϭ 0.5 was assumed. Bufuralol excretion data from dogs could not be found, but human studies have demonstrated a wide range of metabolic clearances probably due to the polymorphic CYP2D6 enzyme (Dayer et al., 1986) . The human extensive metabolizer value of f m,in vivo ϭ 0.8 was used due to the high in vitro and in vivo dog clearance determined here. Caffeine metabolism is extensive in humans (Ͼ95%) (Callahan et al., 1982) and dogs (96%) (Aldridge and Neims, 1979) , where a majority of the dose is excreted in urine as oxidative metabolites. Sixty-six percent of the administered dose in dogs was previously recovered as characterized metabolites, but 96% was recovered as metabolites relative to total urinary constituents (Aldridge and Neims, 1979) . Caffeine undergoes extensive sequential metabolism, but several of the metabolites have been shown to be formed by P450, therefore a value of f m,in vivo ϭ 0.96 was used.
The impact of intestinal metabolism on midazolam AUC was estimated using F a ϫ F g calculated by oral bioavailability, the determined intravenous plasma clearance of 24.7 ml/min/kg corrected using the human B:P partitioning ratio of 0.86 (Gorski et al., 1998) and liver blood flow (35 ml/min/kg) (Benet et al., 1996) . F a , the fraction absorbed, is high for midazolam in humans after correction for its high extraction (Gorski et al., 1998 ) therefore a value of 1 was used, allowing the estimation of F g as 0.334. This in vivo F g approximation assumes that intestinal metabolism of an intravenously administered drug is negligible, as is any active drug transport. In vitro methods have also been evaluated for estimating F g,i /F g , but both in vivo and in vitro methods have been useful for high intestinal extraction drugs with minimal active drug transport potential (Galetin et al., 2008) . Complete intestinal inhibition (F g,i ϭ 1) was used as a conservative assumption based on the large doses of inhibitors present in the gut and because dissolved drug levels could not be characterized. The midazolam F g,i /F g value (0.299) was also used for temazepam based on the similar rP450 kinetics and high in vivo clearances of the two compounds. The F g,i /F g ratio for midazolam was then multiplied by the hepatic DDI parameters for midazolam and temazepam (eq. 1). Bufuralol is a highly metabolized drug in humans (Balant et al., 1980) , but it does not appear to be subject to extensive intestinal metabolism because a value of F a ϫ F g was estimated to be Ͼ1.0. Oral caffeine is completely absorbed intact in humans (Blanchard and Sawers, 1983) . Therefore, F g,i /F g ratios of 1 were used for bufuralol and caffeine.
Statistical measures of DDI prediction accuracy were not calculated due to the currently small number of DDI-positive studies reported here and elsewhere.
Results
Treatment Toleration. Dosing of bufuralol produced no clinical observations. Temazepam and midazolam appeared to produce occasional mild sedation with euphoria. Caffeine appeared to produce mild excitation in some subjects. Side effects of substrates did not appear to worsen when dosed with inhibitors. Ketoconazole and clomipramine were well tolerated. Fluoxetine and fluvoxamine caused temporary constipation and inappetence in all subjects. Although supratherapeutic doses of fluoxetine and fluvoxamine were desired based on initial DDI estimates (see under Materials and Methods), the side effects were not expected after three doses according to previous studies. Both drugs have been administered once a day orally to dogs at 10 mg/kg for periods longer than 3 days according to the fluoxetine dog product label and a metabolism study of fluvoxamine (Ruijten et al., 1984) . Subjects were examined by veterinarians and recovered spontaneously.
Pharmacokinetics. Relevant pharmacokinetic parameters for P450 substrates and inhibitors used for evaluating rP450-based DDI projection methods are provided in Table 1 . Drug interactions were observed with the substrates caffeine, midazolam, and temazepam, but not with bufuralol (Fig. 1) . The pharmacokinetics of bufuralol were highly variable, somewhat limiting the power to distinguish weak drug interactions. For all positive interactions, T max,obs and half-life were largely unchanged compared with the absence of inhibitors, although the animal numbers and blood sampling times did not allow small changes to be discerned. C max,obs , AUC, and clearance were altered, especially with ketoconazole. Four values of unbound in vivo inhibitor concentrations were gathered or estimated from the pharmacokinetic studies for drug interaction extrapolation. The values generally followed the order C avg,u Ͻ C max,obs,u Ͻ [I] in,u estimated with C avg,u Ͻ [I] in estimated with C max,u (Table 2) .
Plasma Protein and Bactosome Binding. High plasma protein binding was observed for three of the inhibitors (Table 3 ). Fraction unbound values followed the order fluvoxamine Ͼ fluoxetine Ͼ ketoconazole Ͼ clomipramine. Fluvoxamine binding to plasma was much lower than the other inhibitors consistent with the moderate binding of fluvoxamine in human plasma. Significant nonspecific binding was observed for P450 inhibitors in dialysis experiments with control Bactosomes, albeit the fraction unbound was higher than that measured in plasma at the protein concentration tested.
rP450 Inhibition. Inhibition constants (IC 50 or K i ) were determined for several rP450-inhibitor combinations after determining the isoforms with the highest intrinsic clearances for each victim drug (see below) ( Table 4 ). All but one inhibition constant was Ͻ10 M, and the majority of unbound inhibition constants were Ͻ1 M. Although suspected earlier based on liver microsome findings (Kuroha et al., 2002b), ketoconazole was verified to be a potent inhibitor of canine recombinant CYP3A12 (Fig. 2) . Unexpected findings include the higher inhibition of CYP2C21 over CYP2D15 by fluoxetine, and the inhibition of CYP2C21 by clomipramine. rP450 caffeine metabolic activity was very low and required high enzyme and caffeine concentrations to detect metabolites. Therefore, phenacetin was used as a substrate in CYP1A1 inhibition experiments.
In Vitro Drug Clearance and f m,P450 Determination. Canine recombinant CYP2B11 and CYP2C21 demonstrated the highest activity toward midazolam and temazepam clearance in substrate depletion experiments (Table 5 ). In vitro bufuralol clearance values were similar with recombinant CYP2D15 and CYP2C21. The midazolam and temazepam findings were consistent with previous 1Ј-hydroxy- , but the involvement of CYP2C21 in bufuralol clearance suggests that it metabolizes a position other than the 1Ј-position metabolized selectively by CYP2D15 (Shou et al., 2003) . Caffeine metabolism by liver microsomes and all rP450s was low, therefore substrate titration kinetics and ISEF activity correction could not be performed. However, under high caffeine concentrations (50 M), CYP1A1, CYP2B11, and CYP2C21 were found to form paraxanthine. Low levels of trimethyluric acid and theophylline were also formed by CYP1A1 and CYP2B11, respectively. CYP2D15 and CYP3A12 did not produce any detectable caffeine metabolites. Because paraxanthine was the major observed metabolite from rP450s, the relative Table 3 ). With one exception, all of the canine Bactosome rP450 ISEF values for the studied substrates were no more than 10-fold above or below unity (Table 5 ). The rank order of ISEF values for midazolam metabolism by all active metabolic pathways were the same for V and V/K calculations when midazolam kinetics were used for each P450 isoform. V ISEF results are not shown because they tended to be more sensitive to the probe substrate used and therefore resulted in more heavily weighted f m values and less accurate DDI magnitude predictions than V/K ISEFs. The rank order of ISEF values for temazepam (Table 5 ) and [I] in vivo (Table 2) values derived using alternate methods were evaluated for predicting AUC i /AUC. A commonly used estimate of [I] in vivo , hepatic inlet [I] in,u calculated with C max , overestimated the DDI magnitudes for bufuralol, intravenous midazolam, and temazepam using ISEF-generated f m,P450 . Overall, [I] in,u calculated with C avg provided the best DDI estimates across different f m,in vivo values and victim drugs as shown in Table 6 . Use of systemic C max,u or C avg,u alone underestimated all interactions. Using the abundanceonly approach to derive f m,P450 with [I] in,u (C avg ) resulted in overestimation of bufuralol and underestimation of caffeine, midazolam, and temazepam interactions.
Discussion
Dogs pose an interesting challenge in P450-mediated DDI assessments because most of the enzymes have not been adequately characterized, but also because dogs are often treated off-label with a number of human drugs with sometimes little idea of DDI risk. Therefore, it is suggested that more drugs administered to dogs be further profiled using in vitro methods to identify potential DDI victims and perpetrators. The use of rP450s in particular provides data that, over time, could stimulate the investigation of pharmacokinetic DDIs in dogs. For example, reporting P450 intrinsic clearance and inhibition values in the literature helps investigators identify potential interacting drugs. It also helps the identification or design of better P450 probe substrates and inhibitors by building up structure-activity relationships specific to dog P450s. In addition, rP450 profiling has enabled the prediction of DDI magnitude, but this result has been limited to human research. Currently, few examples of positive DDIs have been reported for dogs and even fewer attempts have been made to predict them in a quantitative manner. To evaluate the utility of canine rP450s in DDI projection, we have attempted to, retrospectively, relate the magnitude of pharmacokinetic interactions in dogs to the inhibition of specific P450s.
Interactions in dogs involving ketoconazole have previously been attributed to CYP3A pathways (Kuroha et al., 2002a (Kuroha et al., , 2004 . In particular, the human ketoconazole-midazolam interaction is very established so it is usually the first substrate/inhibitor pair to be tested in vitro with liver microsomes from lesser characterized species. In addition, CYP3A probes such as midazolam are cleared quickly in dog liver microsomes, and ketoconazole was demonstrated to have submicromolar inhibition constants against midazolam in liver microsomes (Kuroha et al., 2002b; Aidasani et al., 2008) . Similar in vivo interactions were reproduced here with ketoconazole and midazolam (Table 5) , and ketoconazole was verified to be a very potent inhibitor of recombinant CYP3A12. However, the relatively low activity of CYP3A12 toward midazolam relative to CYP2B11 is notable. High plasma concentrations of ketoconazole coupled with a high f m,P450 and moderate K i for CYP2B11 appeared to explain the majority of the observed midazolam AUC i /AUC ratios.
One observation that may explain the low turnover of midazolam by recombinant CYP3A12 is the lower P450 oxidoreductase content of CYP3A12 versus CYP2B11 Bactosomes or lack of cytochrome b 5 . However, the difference in relative P450/ reductase ratios (ϳ3.7-fold) is much smaller than the CL int,app differences between the two enzymes. Lower activity of canine CYP3A12 toward the typical CYP3A substrates nifedipine and testosterone has also been shown independently with baculovirus-expressed CYP3A12 compared with human CYP3A4 (Carr et al., 2006) . Some amount of fortuitous prediction results also cannot be ruled out with the number of calculations and assumptions made in the DDI extrapolations. However, dog liver is known to express a significant amount of CYP2B11 enzyme (and CYP2C21), which is thought to influence the disposition of veterinary drugs.
As might be expected, the oral midazolam-ketoconazole interaction would be underestimated without the inclusion of an estimate for intestinal P450 inhibition. Intestinal extraction is known to play a large role in human midazolam interactions. Dog CYP3A-like activities and mRNA levels have been reported (Kyokawa et al., 2001; Mealey et al., 2008) , but the authors are not aware of other activities/ isoforms having been quantitatively assessed in canine intestinal tissue. Therefore, it has been assumed here that there is an intestinal DDI component resulting from P450 inhibition with the realization that the exact contribution of CYP3A, CYP2B, or CYP2C enzymes remains unknown. It is unfortunate that there are as many difficulties in estimating intestinal P450 inhibition (i.e., F g,i /F g ratio) as there are in extrapolating hepatic P450 inhibition, including choice of blood flow values, in vivo enterocyte inhibitor concentrations, confounding drug transporter activities, drug permeability, and the potential for inhibitor metabolism (Galetin et al., 2008) . Thus, the minimalistic approach using in vivo pharmacokinetic data were used to estimate F g , and the most conservative estimate of F g,i ϭ 1 was used to avoid overinterpretation. This approach appeared to explain the difference between DDI magnitude from intravenous and oral midazolam.
Large temazepam interactions were also noted with ketoconazole despite the expectation that there would be a larger contribution of conjugation clearance than is observed with midazolam (Schwarz, 1979) . Still, the selective CL int,app (Table 5 ) and turnover of temazepam to oxazepam by CYP2B11 (Shou et al., 2003) suggested that temazepam may be a suitable in vivo probe of this enzyme. As with midazolam, the estimates of f m,P450 were high for CYP2B11. K i,u and [I] in vivo,u values provided surprisingly good DDI estimates using maximal P450 in vivo clearance and an intestinal first-pass effect of equal magnitude to midazolam. On the other hand, use of dog in vivo excretion data (f m,in vivo ϭ 0.5) underestimated the temazepam-ketoconazole interaction due to glucuronide clearance. Excluding intestinal inhibition further underestimated the interaction regardless of the [I] in vivo value used. Without further data, it is difficult to hypothesize the reason for low DDI prediction, but it is conjectured that intestinal P450 inhibition, as well as the following factors, may be involved: 1) intestinal or hepatic transporter interactions between temazepam and ketoconazole, 2) inhibition of glucuronidation by ketoconazole, or 3) underestimation the P450 f m,in vivo value at a 1 mg/kg dose because of P450 saturation by the 20 mg/kg dose used in the excretion study (Schwarz, 1979) .
Very high plasma exposures of fluoxetine were observed, but no measurable bufuralol DDI was observed with fluoxetine as an inhibitor. This result is despite the fact that the long-lived fluoxetine metabolite, norfluoxetine, is also a P450 inhibitor. Bufuralol is extensively metabolized in humans (Dayer et al., 1986 ) with involvement of P450 that appears to be sensitive to the numerous CYP2D6 genotypes. In dogs, little bufuralol is excreted unchanged (Francis et al., 1976) , but the precise f m,in vivo value for oxidative P450 metabolism could not be estimated for dogs without quantitation of unchanged drug and metabolites. It is speculated that the choice of f m,in vivo value may be partly responsible for the overestimation of a fluoxetine interaction. For instance, although there are clearly multiple oxidative elimination pathways for bufuralol according to rP450 phenotyping, there is also evidence for direct conjugation in vivo (Francis et al., 1976) . Because the approved canine drug clomipramine produced a low IC 50 in dog liver microsomes (ϳ0.1 M) (Aidasani et al., 2008 ), this drug was tested next as an inhibitor of bufuralol. However, inhibition of recombinant CYP2D15 by clomipramine turned out to be less potent than in liver microsomes (Table 4) . Very high plasma protein binding also probably limits the P450 inhibition potential of clomipramine in vivo.
Fluvoxamine produced a small DDI with caffeine, and in vitro-in vivo extrapolation provided a reasonable estimate of the true interaction magnitude using the CYP1A1 inhibition value. Despite fluvoxamine having the lowest plasma concentrations of all inhibitors, the estimated unbound fluvoxamine concentration in the liver was high ( Table 2 ). The interaction magnitude is suggested to be minor because of a moderate estimated f m,P450 value for CYP1A1 resulting from contributing clearance by CYP2B11 and CYP2C21. A similar interaction was obtained with theophylline and enrofloxacin in dogs, providing further evidence that the interaction does occur at a CYP1A pathway(s) in vivo (Intorre et al., 1995) . Dog liver does express both CYP1A1 and CYP1A2 isoforms (Uchida et al., 1990) , but the analysis of CYP1A1 alone does not appear to be responsible for the modest underestimation of the DDI. Instead, caffeine generally appears to be an insensitive marker of CYP1A activity in dogs based on in vitro data. Caffeine turnover in vitro was very low even with liver microsomes (containing CYP1A2). This finding was also reported by Mise et al. (2008) who studied the effect of the 1117 C3 T nonfunctional CYP1A2 genotype (Tenmizu et al., 2004) on liver microsome activity. Caffeine metabolism was low in both mutant and wild-type dog liver microsomes, suggesting that CYP1A2 provides a smaller contribution to caffeine metabolism in dogs relative to humans.
Whereas the magnitude of dog DDIs could be rationalized in some of the cases presented, it is important to recall that there are many assumptions involved in the extrapolation methods. In addition, the drugs tested here have a long history and much is known about them. In early veterinary drug discovery, estimates of f m,in vivo are not available and the inhibition potential of metabolites may not be known. The conservative assumptions that f m,in vivo ϭ 1 and F g,i ϭ 1 would be expected to overpredict DDIs until victim drugs are further characterized. Further complexities also surround the assumptions and parameter estimates used for predicting intestinal metabolism and its inhibition, which can clearly affect DDI estimates. When using rP450, specific f m,P450 values are integral in DDI predictions, and this result may be problematic because the only published hepatic P450 abundance levels may not be completely isoform specific. Therefore, differentiation of some isoforms within the same subfamily (e.g., CYP3A12 and CYP3A26) is not yet possible. The choice of substrates used to determine liver microsome ISEF values also requires further evaluation because they are used in the derivation of f m,P450 .
In summary, pharmaceutical development for companion animals continues to grow and expand into new therapeutic areas, but there are few methods for assessing pharmacokinetic drug interactions. Herein, methods commonly used to project P450-mediated DDI magnitude in humans were shown to provide reasonable DDI estimates in dogs for some victim drugs where in vivo parameters were available or could be estimated (e.g., f m,in vivo , F g,i /F g ). At minimum, it is proposed that the relative f m,P450 values, the assumption of f m,in vivo ϭ 1, [I] in,u , and K i,u may be used to provide early discovery estimates of the worstcase scenario DDI for dogs. rP450 also reveals some of the enzymes probably involved in dog DDIs-something that is severely lacking even for established drugs. Furthermore, the development of more selective in vivo substrates and inhibitors of dog P450s would benefit the testing of new drug leads and other agents used off-label, and it would help in the refinement of DDI prediction methods. Given more selective P450 probes, the dog might even serve human health as a model in which to characterize the actual hepatic portal vein and intestinal drug concentrations that consistently yield the most accurate DDI extrapolations.
